Outcomes after SynCardia ® temporary total artificial heart implantation: A 20‐year single‐center experience in 196 patients
Artificial Organs · 2025
DOI: 10.1111/aor.14860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Artyom Razumov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University of Bochum, Bad Oeynhausen, Germa…. Hauptthemen laut MEDLINE: Heart, Artificial, Heart Failure, Heart-Assist Devices. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The SynCardia® temporary total artificial heart (TAH) serves as a mechanical circulatory support device for patients suffering from irreversible biventricular failure.
Methods
This retrospective study analyzed 196 consecutive patients who underwent TAH implantation at our center from 2001 to 2021. We assessed survival rates and all‐cause mortality during TAH support, including survival post‐heart transplantation.
Results
The median age of patients was 55 years, with 88% being male. The primary diagnoses included cardiomyopathy (43.9%), acute myocardial infarction (26.5%), and postcardiotomy heart failure (15.5%). At implantation, 87.2% of patients were classified as INTERMACS Profile 1. The median duration of support was 96 days (IQR: 23–227). Survival rates at 1, 6, and 12 months were 72%, 41%, and 34%, respectively. Postoperative rethoracotomy was necessary in 44.4% of patients; 39.3% experienced neurological events and 24.6% developed gastrointestinal bleeding. Overall, 64.8% of patients died while on support, primarily due to multiple organ failure (55.9%). Factors such as older age, higher bilirubin levels, postcardiotomy and specific underlying diagnoses were independent predictors of mortality during TAH support. On a positive note, 35.2% of patients underwent successful heart transplants, with 1‐, 5‐, and 10‐year posttransplant survival rates of 65%, 58%, and 51%, respectively.
Conclusions
While high mortality rates persist among patients with biventricular failure, the SynCardia® TAH offers a viable interim solution for critically ill patients, particularly those who can be successfully bridged to heart transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University of Bochum, Bad Oeynhausen, Germany.
- Department of Cardiovascular Surgery, German Heart Centre Munich, Technical University of Munich, Munich, Germany.
ORCID-Profile: Artyom Razumov, Darko Radakovic, Henrik Fox
Zitieren
APA
Razumov, A., Burri, M., Zittermann, A., Radakovic, D., Lauenroth, V., Rojas, S. V., Fox, H., Schramm, R., Gummert, J., Deutsch, M. A., & Morshuis, M. (2025). Outcomes after SynCardia ® temporary total artificial heart implantation: A 20‐year single‐center experience in 196 patients. Artificial Organs. https://doi.org/10.1111/aor.14860
Vancouver
Razumov A, Burri M, Zittermann A, Radakovic D, Lauenroth V, Rojas SV, et al. Outcomes after SynCardia ® temporary total artificial heart implantation: A 20‐year single‐center experience in 196 patients. Artificial Organs. 2025. doi:10.1111/aor.14860
BibTeX
@article{Razumov2025,
author = {Razumov, Artyom and Burri, Melchior and Zittermann, Armin and Radakovic, Darko and Lauenroth, Volker and Rojas, Sebastian V and Fox, Henrik and Schramm, René and Gummert, Jan and Deutsch, Marcus-André and Morshuis, Michiel},
title = {Outcomes after SynCardia ® temporary total artificial heart implantation: A 20‐year single‐center experience in 196 patients},
journal = {Artificial Organs},
year = {2025},
doi = {10.1111/aor.14860}
}
EUVIMED